Share

Diagnostics Digest

A podcast by CM Life Science

Led by specialist consultant Nathan Sharpe, Diagnostics Digest invites thought leaders to discuss industry insights and the latest news and trends in the diagnostics space.Nathan works across Point-of-Care Diagnostics on
Latest Episode9/1/2022

Adapting to Survive: Rapid Testing Strategies with COVID's Chief Pathology Advisor.

Season 1, Ep. 3
In this episode of Diagnostics Digest, a CM Life Science series discussing trends and insights into the diagnostics market, I speak with David Wells, Chief Executive Officer of the Institute of Biomedical Science (IBMS).With over 21,000 members in 74 countries, IBMS is the leading professional body for scientists, support staff and students in the field of biomedical science. For over 100 years, it has been dedicated to the promotion, development and delivery of excellence in biomedical science within all aspects of healthcare, and to providing the highest standards of service to patients and the public.We discuss the NHS response to rapid testing, the importance of the IBMS and its members as an organisation and what's to come during its biggest conference. Until June 2021 David led the NHS England and NHS Improvement Pathology consolidation programme, seeking to deliver efficient, high quality and innovative pathology services across England.Now appointed Chief Executive of the IBMS, as an expert advising on policy, strategy and technology deployment, he shares fascinating insights from his experiences at the helm of the biggest healthcare challenge the world has ever seen.If you'd like to chat some more about the themes in this episode, are keen to feature on a podcast yourself or want to learn more about CM Life Science's services; then please drop me a message at nathan.sharpe@lifesci-cm.com or let's connect on LinkedIn.
9/1/2022

Adapting to Survive: Rapid Testing Strategies with COVID's Chief Pathology Advisor.

Season 1, Ep. 3
In this episode of Diagnostics Digest, a CM Life Science series discussing trends and insights into the diagnostics market, I speak with David Wells, Chief Executive Officer of the Institute of Biomedical Science (IBMS).With over 21,000 members in 74 countries, IBMS is the leading professional body for scientists, support staff and students in the field of biomedical science. For over 100 years, it has been dedicated to the promotion, development and delivery of excellence in biomedical science within all aspects of healthcare, and to providing the highest standards of service to patients and the public.We discuss the NHS response to rapid testing, the importance of the IBMS and its members as an organisation and what's to come during its biggest conference. Until June 2021 David led the NHS England and NHS Improvement Pathology consolidation programme, seeking to deliver efficient, high quality and innovative pathology services across England.Now appointed Chief Executive of the IBMS, as an expert advising on policy, strategy and technology deployment, he shares fascinating insights from his experiences at the helm of the biggest healthcare challenge the world has ever seen.If you'd like to chat some more about the themes in this episode, are keen to feature on a podcast yourself or want to learn more about CM Life Science's services; then please drop me a message at nathan.sharpe@lifesci-cm.com or let's connect on LinkedIn.
8/9/2022

Challenging Diversity in Diagnostics and Beyond.

Season 1, Ep. 2
In this episode of Diagnostics Digest, a CM Life Science series discussing trends and insights into the diagnostics market, I speak with Beth Cobb, Chief Operating Officer at NOWDiagnostics | NowDx.NOWDx is on a mission to develop rapid, accurate, affordable, and easy-to-administer over-the-counter and point-of-care diagnostic tests that return results in minutes. This innovative product is accompanied by a vision to create a world with vastly improved access to accurate healthcare information. Through providing access to quick and easy at home testing, patients and caregivers become empowered with the knowledge and understanding to truly change the future of disease management.In this episode, we discuss diversity and gender equality in the start-up and diagnostics space, and what this landscape means for the future of NOWDx and others in the market. Priding themselves on striving to make a difference to people's lives, both colleagues and customers, Beth delves into the challenges and strategies she has experiences when doing just that.Whether you’re in the diagnostics industry or not, this episode promises invaluable insight for those looking to change their company DEI agenda for the better.If you'd like to chat some more about the themes in this episode, are keen to feature on a podcast yourself or want to learn more about CM Life Science's services; then please drop me a message at nathan.sharpe@lifesci-cm.com or let's connect on LinkedIn.